JP2011526926A5 - - Google Patents

Download PDF

Info

Publication number
JP2011526926A5
JP2011526926A5 JP2011516860A JP2011516860A JP2011526926A5 JP 2011526926 A5 JP2011526926 A5 JP 2011526926A5 JP 2011516860 A JP2011516860 A JP 2011516860A JP 2011516860 A JP2011516860 A JP 2011516860A JP 2011526926 A5 JP2011526926 A5 JP 2011526926A5
Authority
JP
Japan
Prior art keywords
fluoro
amide
carboxylic acid
phenylamino
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011516860A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011526926A (ja
JP5544358B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/049453 external-priority patent/WO2010003025A1/en
Publication of JP2011526926A publication Critical patent/JP2011526926A/ja
Publication of JP2011526926A5 publication Critical patent/JP2011526926A5/ja
Application granted granted Critical
Publication of JP5544358B2 publication Critical patent/JP5544358B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011516860A 2008-07-01 2009-07-01 置換二環式ヘテロ環化合物と使用方法 Expired - Fee Related JP5544358B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7742608P 2008-07-01 2008-07-01
US61/077,426 2008-07-01
PCT/US2009/049453 WO2010003025A1 (en) 2008-07-01 2009-07-01 Bicyclic heterocycles as mek kinase inhibitors

Publications (3)

Publication Number Publication Date
JP2011526926A JP2011526926A (ja) 2011-10-20
JP2011526926A5 true JP2011526926A5 (US20070167479A1-20070719-C00034.png) 2012-08-16
JP5544358B2 JP5544358B2 (ja) 2014-07-09

Family

ID=41038842

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011516860A Expired - Fee Related JP5544358B2 (ja) 2008-07-01 2009-07-01 置換二環式ヘテロ環化合物と使用方法

Country Status (15)

Country Link
US (1) US8841462B2 (US20070167479A1-20070719-C00034.png)
EP (1) EP2310373A1 (US20070167479A1-20070719-C00034.png)
JP (1) JP5544358B2 (US20070167479A1-20070719-C00034.png)
KR (1) KR20110029161A (US20070167479A1-20070719-C00034.png)
CN (1) CN102137847B (US20070167479A1-20070719-C00034.png)
AU (1) AU2009266956B2 (US20070167479A1-20070719-C00034.png)
BR (1) BRPI0910175A2 (US20070167479A1-20070719-C00034.png)
CA (1) CA2727250A1 (US20070167479A1-20070719-C00034.png)
CL (1) CL2010001641A1 (US20070167479A1-20070719-C00034.png)
IL (1) IL209931A0 (US20070167479A1-20070719-C00034.png)
MX (1) MX2010014559A (US20070167479A1-20070719-C00034.png)
PE (1) PE20110570A1 (US20070167479A1-20070719-C00034.png)
RU (1) RU2509078C2 (US20070167479A1-20070719-C00034.png)
WO (1) WO2010003025A1 (US20070167479A1-20070719-C00034.png)
ZA (1) ZA201008963B (US20070167479A1-20070719-C00034.png)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201200651A1 (ru) 2009-11-04 2012-12-28 Новартис Аг Гетероциклические сульфонамидные производные, применимые в качестве ингибиторов мек
AU2012265844A1 (en) * 2009-12-08 2013-05-02 Novartis Ag Heterocyclic sulfonamide derivatives
CN102020651B (zh) 2010-11-02 2012-07-18 北京赛林泰医药技术有限公司 6-芳基氨基吡啶酮甲酰胺mek抑制剂
AU2013337702A1 (en) 2012-11-02 2015-05-21 Merck Patent Gmbh Method of reducing adverse effects in a cancer patient undergoing treatment with a MEK inhibitor
US9227969B2 (en) 2013-08-14 2016-01-05 Novartis Ag Compounds and compositions as inhibitors of MEK
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
NO2714752T3 (US20070167479A1-20070719-C00034.png) 2014-05-08 2018-04-21
CN104119332B (zh) * 2014-07-08 2019-03-29 上海科州药物研发有限公司 作为蛋白激酶抑制剂的苯并杂环化合物及其制备方法和用途
CN104860869B (zh) * 2015-04-03 2017-11-03 北京大学 具有mek激酶抑制功能的化合物及其制备方法与应用
HUE050317T2 (hu) 2015-05-20 2020-11-30 Amgen Inc APJ receptor triazol agonistái
WO2017033113A1 (en) 2015-08-21 2017-03-02 Acerta Pharma B.V. Therapeutic combinations of a mek inhibitor and a btk inhibitor
GB201516504D0 (en) 2015-09-17 2015-11-04 Astrazeneca Ab Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
AU2017249229A1 (en) 2016-04-15 2018-10-04 Genentech, Inc. Diagnostic and therapeutic methods for cancer
WO2017192485A1 (en) 2016-05-03 2017-11-09 Amgen Inc. Heterocyclic triazole compounds as agonists of the apj receptor
HUE057733T2 (hu) 2016-10-28 2022-06-28 Chia Tai Tianqing Pharmaceutical Group Co Ltd Neuropátiás faktor tirozinkináz receptor inhibitorként alkalmazott amino-pirazolopirimidin vegyület
WO2018093580A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Triazole pyridyl compounds as agonists of the apj receptor
WO2018093579A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Triazole phenyl compounds as agonists of the apj receptor
EP3541805B1 (en) 2016-11-16 2020-10-14 Amgen Inc. Heteroaryl-substituted triazoles as apj receptor agonists
MA46824A (fr) 2016-11-16 2019-09-25 Amgen Inc Composés de triazole substitués par alkyle en tant qu'agonistes du récepteur apj
US10736883B2 (en) 2016-11-16 2020-08-11 Amgen Inc. Triazole furan compounds as agonists of the APJ receptor
WO2018093577A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Cycloalkyl substituted triazole compounds as agonists of the apj receptor
AU2018329925A1 (en) 2017-09-08 2020-03-05 F. Hoffmann-La Roche Ag Diagnostic and therapeutic methods for cancer
EP3704122B1 (en) 2017-11-03 2021-09-01 Amgen Inc. Fused triazole agonists of the apj receptor
EP3752200A1 (en) 2018-02-13 2020-12-23 Vib Vzw Targeting minimal residual disease in cancer with rxr antagonists
US11807624B2 (en) 2018-05-01 2023-11-07 Amgen Inc. Substituted pyrimidinones as agonists of the APJ receptor
JP2023504623A (ja) * 2019-12-04 2023-02-06 アーカス バイオサイエンシーズ,インコーポレーテッド Hif-2アルファの阻害剤
CN113336786B (zh) * 2021-05-31 2022-10-18 南京工业大学 一种非对映选择性的多取代环烷基化合物及其制备方法
WO2024033381A1 (en) 2022-08-10 2024-02-15 Vib Vzw Inhibition of tcf4/itf2 in the treatment of cancer

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2017853C3 (de) 1970-04-14 1975-12-11 Standard Elektrik Lorenz Ag, 7000 Stuttgart Steuerverfahren zur Sicherung der Informationsverarbeitung und -Übertragung
ZA711710B (en) * 1970-05-28 1971-12-29 Squibb & Sons Inc Amino derivatives of purazolo-pyridine carboxylic acids and esters
US3736326A (en) * 1971-03-29 1973-05-29 Squibb & Sons Inc Isoxazolopyridine carboxylic acids and esters
US3780047A (en) * 1972-07-05 1973-12-18 Squibb & Sons Inc Derivatives of pyrazolo(3',4'-2,3)pyrido(4,5-e)b-benzo-1,5-diazepines
US4012373A (en) * 1972-09-22 1977-03-15 E. R. Squibb & Sons, Inc. Pyrazolo[3',4'-2,3]pyrido[4,5-e]b-benzo-1,5-diazepinones
GB8404586D0 (en) * 1984-02-22 1984-03-28 Beecham Group Plc Compounds
JP2002020386A (ja) * 2000-07-07 2002-01-23 Ono Pharmaceut Co Ltd ピラゾロピリジン誘導体
CN1219753C (zh) 2000-07-19 2005-09-21 沃尼尔·朗伯公司 4-碘苯氨基苯氧肟酸的氧合酯
US20050009876A1 (en) * 2000-07-31 2005-01-13 Bhagwat Shripad S. Indazole compounds, compositions thereof and methods of treatment therewith
UA76837C2 (uk) 2002-03-13 2006-09-15 Еррей Байофарма Інк. N3 алкіловані похідні бензімідазолу як інгібітори мек
ES2549159T3 (es) 2002-03-13 2015-10-23 Array Biopharma, Inc. Derivados de bencimidazol N3-alquilados como inhibidores de MEK
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
CL2003002287A1 (es) * 2002-11-25 2005-01-14 Wyeth Corp COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS
GB0316237D0 (en) 2003-07-11 2003-08-13 Astrazeneca Ab Therapeutic agents
GB0316232D0 (en) 2003-07-11 2003-08-13 Astrazeneca Ab Therapeutic agents
US20050049276A1 (en) * 2003-07-23 2005-03-03 Warner-Lambert Company, Llc Imidazopyridines and triazolopyridines
ATE506953T1 (de) 2003-08-07 2011-05-15 Rigel Pharmaceuticals Inc 2,4-pyrimidindiamin-verbindungen und verwendungen als antiproliferative mittel
US7144907B2 (en) * 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US7538120B2 (en) * 2003-09-03 2009-05-26 Array Biopharma Inc. Method of treating inflammatory diseases
DK1689233T3 (da) * 2003-11-19 2012-10-15 Array Biopharma Inc Bicykliske inhibitorer af MEK
ES2299906T3 (es) 2003-11-25 2008-06-01 Eli Lilly And Company Moduladores de receptores activados por proliferadores de peroxisomas.
AU2004299438A1 (en) 2003-12-19 2005-06-30 Biovitrum Ab Novel benzofuran derivatives, which can be used in prophylaxis or treatment of 5-HT6 receptor-related disorder
ES2338060T3 (es) 2003-12-22 2010-05-03 Basilea Pharmaceutica Ag Componentes de tipo ariloxi y ariltoxia-cetofenona para el tratamiento del cancer.
EP1699488A2 (en) 2003-12-23 2006-09-13 Pfizer Products Incorporated Therapeutic combination for cognition enhancement and psychotic disorders
JP2009507024A (ja) 2005-09-01 2009-02-19 アレイ バイオファーマ、インコーポレイテッド Raf阻害剤化合物およびその使用方法
EA025871B9 (ru) * 2005-10-07 2017-08-31 Экселиксис, Инк. Ингибиторы mek и способы их применения
US20100063066A1 (en) 2006-08-31 2010-03-11 Array Biopharma, Inc. Raf inhibitor compounds and methods of use thereof

Similar Documents

Publication Publication Date Title
JP2011526926A5 (US20070167479A1-20070719-C00034.png)
EP3259271B1 (en) Fluorinated derivatives of 3-(2-oxo-3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)imidazolidin-1-yl)propanoic acid and uses thereof
JP2014037426A5 (US20070167479A1-20070719-C00034.png)
JP2011507888A5 (US20070167479A1-20070719-C00034.png)
HRP20160036T1 (hr) Određeni kemijski entiteti, priprave i metode koji sadrže imidazopirimidin
JP2006182786A5 (US20070167479A1-20070719-C00034.png)
JP2008517913A5 (US20070167479A1-20070719-C00034.png)
TW201026676A (en) A method of inhibiting hepatitis C virus by combination of a 5,6-dihydro-1H-pyridin-2-one and one or more additional antiviral compounds
WO2006098918A3 (en) Substituted gamma lactams as therapeutic agents
CN106008488B (zh) 氰基吲哚类衍生物及其制备方法和用途
JP2012502067A5 (US20070167479A1-20070719-C00034.png)
EA022527B1 (ru) 2-ЗАМЕЩЕННЫЕ-8-АЛКИЛ-7-ОКСО-7,8-ДИГИДРОПИРИДО[2,3-d]ПИРИМИДИН-6-КАРБОНИТРИЛЫ И ИХ ПРИМЕНЕНИЕ
JP2018501315A5 (US20070167479A1-20070719-C00034.png)
JPWO2012144463A1 (ja) 腫瘍治療剤
JP2012524110A5 (US20070167479A1-20070719-C00034.png)
CA2983312A1 (en) Tetrahydronaphthyridinyl propionic acid derivatives and uses thereof
RU2007125659A (ru) Фенилпиперазиновые производные с сочетанием свойств неполного агонизма к рецепторам дофамина-d2 и ингибирования повторного поглощения серотонина
TW201010990A (en) New combination-408
JP2012505879A5 (US20070167479A1-20070719-C00034.png)
HU229137B1 (en) 8,8a-dihydro-indeno[1,2-d]thiazole derivatives having sulphoneamid- or sulphone substitutents in the 2 position, method for production thereof and use thereof as a medicament
KR20170091154A (ko) 섬유증의 소분자 억제제
RU2011110745A (ru) [4-(5-аминометил-2-фторфенил)-пиперидин-1-ил]-[7-фтор-1-(2-метоксиэтил)-4-трифторметокси-1н-индол-3-ил]-метанон как ингибитор триптазы тучных клеток
JP2005538974A5 (US20070167479A1-20070719-C00034.png)
SK77096A3 (en) 6-(2-imidazolinylamino)quinoline compounds useful as alpha-2 adreno-receptor agonists
JP2007527903A5 (US20070167479A1-20070719-C00034.png)